Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Just when investors thought things couldn't get any worse, they do.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The UK company buys IRDx for $1bn.
